IL17A and asthma: Finally, a new and potent RORγt inhibitor, administered in a mouse model of house dust mite-induced asthma which exhibited a transcriptomic signature overlapping with that of a cluster of patients with severe neutrophilic asthma from the U-BIOPRED cohort, showed a decrease in IL-22, IL-17, and CXCL1 levels in BAL fluid, in BAL neutrophilia and more interestingly an improvement in airway resistances in a dose dependent manner (108).